Food & Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food & Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
BioCryst Pharmaceuticals, Inc.
Orphan drug status granted for BCX-1777 in two additional cancer indications
September 24th, 2004
BioCryst Pharmaceuticals, Inc., (BCRX) announced that forodesine hydrochloride, its lead anticancer compound formerly known as BCX-1777 (forodesine), has been granted designation as an "Orphan Drug" for two additional cancer indications by the U.S. Food and Drug Administration (FDA). The company is developing forodesine for treatment of T-cell mediated cancers, and a phase IIa clinical trial in patients with T-cell leukemia is in progress. Forodesine, a purine nucleoside phosphorylase (PNP) inhibitor which functions by blocking the T-cell's ability to synthesize DNA, was granted orphan status for treatment of T-cell non-Hodgkin lymphoma, including cutaneous T-cell...
Source: Food & Drug Law Weekly (2004-09-24)
|
